Retatrutide: a beginner's guide to the triple agonist

Key takeaways

• Retatrutide (also called LY3437943) is a triple-hormone-receptor agonist: one weekly injection that switches on three gut and metabolic receptors at once, GIP, GLP-1, and glucagon . Eli Lilly is developing it for obesity, and it is still in Phase 3 trials .
• It is not FDA-approved. There is no approved dose, no label, and no legal way to buy the real thing; it is available only to people enrolled in Lilly's clinical trials .
• The weight-loss numbers are large, which is the whole reason for the attention, but the evidence is early and no study has compared it head to head with semaglutide or tirzepatide. In the one peer-reviewed trial (Phase 2, 338 adults, 48 weeks), body weight fell 24.2 percent at the top 12 mg dose, versus 2.1 percent on placebo .
• The Phase 3 figures people quote are company press-release toplines, not peer-reviewed results. Lilly reported up to 28.7 percent loss at 12 mg in one trial (68 weeks) and 28.3 percent in another (80 weeks), on the estimate that assumes people stayed on the drug the whole time .
• The common side effects are gut-related (nausea, diarrhea, vomiting, constipation) . A newer, dose-related signal is dysesthesia, an altered-touch sensation, reported in 20.9 percent of the 12 mg group versus 0.7 percent on placebo in one Phase 3 trial .
• Anything sold online as retatrutide is not the trial drug. The FDA says it cannot be legally compounded, is not a component of any approved drug, and has warned about products falsely labeled for research use but sold for people to inject .

The short version: huge trial numbers, but still investigational

Retatrutide is a peptide Eli Lilly built to switch on three receptors at once, which is why people call it a triple agonist: GIP, GLP-1, and glucagon . GLP-1 and GIP are the gut-hormone targets today's weight-loss shots already use; adding glucagon is the new part, and the design bet is that a third target pushes weight loss further. So far, the trials back that up.

In the studies it is a once-weekly injection under the skin, with the dose stepped up slowly over the first weeks . That is the only setting it legally exists in right now: a Lilly trial. There is no pharmacy version, no approved pen, and no finished vial.

What people are actually chasing here

This is almost entirely about weight. Retatrutide's reputation grew from cross-trial comparisons: put its numbers next to semaglutide's and tirzepatide's and they look larger, so the interest is people hoping for more loss than the approved drugs give them. A lot of the conversation is also just anticipation, waiting to see whether the Phase 3 results hold up and when, or if, it reaches the market.

Here is the honest part. No head-to-head trial pits retatrutide against semaglutide or tirzepatide, so the it-beats-the-others framing rests on comparing separate studies with different people and lengths, which is informative but not proof . And because there is no legal supply, anyone using it today is either in a trial or has bought something from the gray market that may not be the real molecule at all .

What the science shows: one solid trial and two company press releases

The honest evidence picture is one good published trial plus a lot of very new, not-yet-reviewed data. The peer-reviewed base is a single Phase 2 study: 338 adults with obesity, 48 weeks. At the top 12 mg dose, average body weight fell 24.2 percent, against 2.1 percent on placebo, and the weight curves had not flattened out yet . That is a strong result, and it is the one number here that has been through real scientific review.

The bigger figures are Phase 3 press-release toplines, not peer-reviewed trials. In TRIUMPH-4 (445 people, 68 weeks), the 12 mg dose cut weight by 28.7 percent, about 71 pounds, on the efficacy estimand, the figure you get if people stay on the drug .

TRIUMPH-1 was larger, over 2,300 people without diabetes, and ran 80 weeks . There, 12 mg averaged 28.3 percent, about 70 pounds, on that same measure .

So the evidence tier is human but early. One published trial says the drug works, and works big. Two unpublished company readouts say the same at higher doses over longer times. The long-term safety story, and independent review of the Phase 3 data, are both still to come.

The catch: not approved, not legally available, and a new nerve signal

• It is investigational. No FDA-approved dose, no label, no approved use. It is legally available only to people in Eli Lilly's clinical trials . The FDA states it is not a component of any approved drug and has not been found safe and effective for any condition .
• What you buy is not the trial drug. The FDA says retatrutide cannot be used in compounding under federal law, and it has warned about products falsely labeled for research purposes or not for human consumption that are actually sold to people to inject, with dosing instructions . Identity, purity, and real strength of those products are not verified.
• Gut side effects lead the list. Nausea, diarrhea, vomiting, constipation, and reduced appetite were the most common events, dose-related and mostly mild to moderate, and heaviest during the dose-increase weeks . Heavy vomiting or diarrhea can dehydrate you, and this whole drug class can stress the kidneys when someone gets badly dehydrated.
• Dysesthesia is the new one to watch. This is altered touch sensation, where normal contact can feel odd or unpleasant. It showed up in Phase 3 but not in Phase 2, and it climbed with the dose: 8.8 percent at 9 mg and 20.9 percent at 12 mg versus 0.7 percent on placebo in TRIUMPH-4, and 5.1, 12.3, and 12.5 percent at 4, 9, and 12 mg versus 0.9 percent on placebo in TRIUMPH-1 . Nobody has fully explained it yet, and it is being tracked across the remaining trials.
• The glucagon target is the newest part. Retatrutide adds a third receptor, glucagon, on top of the GLP-1 and GIP that current shots use , and that extra target is the piece with the least long-term human track record, because the outcomes trials have not reported yet . Heart rate also rose with the dose in Phase 2, peaking around 24 weeks before easing back .
• Long-term safety is genuinely unknown. The heart and kidney outcomes trial has not reported, and the remaining Phase 3 studies are still open . Big weight loss in a year is not the same as a settled long-term safety record.

How it is used in trials, and why the numbers are not yours to copy

Inside the studies, retatrutide is a once-weekly shot under the skin, and the dose climbs in slow steps over the first weeks rather than starting high, which is how the trials kept the early nausea manageable . That slow ramp is the one habit worth carrying over from the trial design: this class is much rougher on the gut when the dose jumps too fast.

One thing the calculator cannot fix: whether the vial holds what the label claims. Since there is no approved, tested product, the strength printed on a gray-market vial is an assumption, not a verified fact . That single unknown sits underneath every dose decision that follows it.

Where to read more

This guide is the on-ramp. For the full picture, the triple-agonist and TRIUMPH breakdown walks the trials in detail, the weight-loss timeline lays out what changes and when, and the side-effects rundown covers the gut effects and the dysesthesia signal. If you are weighing it against tirzepatide, the retatrutide vs tirzepatide comparison sets the two side by side, and the reconstitution and dosing guide handles the mixing math. The retatrutide library entry is the quick reference for the trial-reference schedule and sources.

How we sourced this, and the fine print

Every claim on this page is pinned to a published source: the peer-reviewed Phase 2 trial on PubMed, the ClinicalTrials.gov records for the Phase 3 studies, Eli Lilly's own topline press releases, and the FDA's statement on unapproved GLP-1 drugs. Where the data is a company topline and not a reviewed trial, this guide says so instead of blurring the two.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 6 entries, all primary or authoritative (PubMed, ClinicalTrials.gov via the US National Library of Medicine, Eli Lilly topline press releases, and the FDA), last reviewed 2026-07-13.

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.